# The Cellular Pharmacology of F-TAF in Dried Blood Spots

> **NCT02962739** · PHASE1 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 38 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** emtricitabine 200 mg/tenofovir alafenamide 25mg

## Key facts

- **NCT ID:** NCT02962739
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2019-05-22
- **Final completion:** 2019-05-22
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2021-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02962739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02962739, "The Cellular Pharmacology of F-TAF in Dried Blood Spots". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT02962739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*